OnKure Therapeutics (NASDAQ:OKUR) Trading 0.6% Higher – What’s Next?

OnKure Therapeutics, Inc. (NASDAQ:OKUR)’s stock price rose 0.6% on Thursday . The stock traded as high as $3.62 and last traded at $3.56. Approximately 132,190 shares traded hands during trading, a decline of 12% from the average daily volume of 149,968 shares. The stock had previously closed at $3.54.

Analyst Ratings Changes

A number of analysts have recently issued reports on OKUR shares. Wall Street Zen raised shares of OnKure Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, June 6th. Oppenheimer restated an “outperform” rating and set a $14.00 target price on shares of OnKure Therapeutics in a research note on Friday, August 14th. HC Wainwright dropped their target price on shares of OnKure Therapeutics to $21.00 and set a “buy” rating for the company in a report on Monday, July 20th. Finally, Weiss Ratings cut OnKure Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, July 28th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, OnKure Therapeutics currently has an average rating of “Hold” and an average target price of $17.50.

OnKure Therapeutics Trading Up 0.6%

The firm has a market capitalization of $144.61 million, a P/E ratio of -1.02 and a beta of 0.23. The company has a 50 day simple moving average of $4.09 and a two-hundred day simple moving average of $4.00.

OnKure Therapeutics (NASDAQ:OKUR) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($0.31) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.23. On average, sell-side analysts expect that OnKure Therapeutics, Inc. will post -1.71 EPS for the current fiscal year.

Institutional Trading of OnKure Therapeutics

Several hedge funds have recently modified their holdings of OKUR. ADAR1 Capital Management LLC raised its position in OnKure Therapeutics by 140.1% during the first quarter. ADAR1 Capital Management LLC now owns 2,434,941 shares of the company’s stock valued at $10,081,000 after purchasing an additional 1,420,783 shares during the period. Vivo Capital LLC purchased a new stake in OnKure Therapeutics during the 1st quarter valued at $7,981,000. Shay Capital LLC lifted its position in OnKure Therapeutics by 17.4% in the third quarter. Shay Capital LLC now owns 917,934 shares of the company’s stock worth $2,524,000 after buying an additional 135,888 shares during the last quarter. Prosight Management LP lifted its position in OnKure Therapeutics by 204.9% in the fourth quarter. Prosight Management LP now owns 816,909 shares of the company’s stock worth $2,369,000 after buying an additional 548,950 shares during the last quarter. Finally, Rosalind Advisors Inc. purchased a new position in OnKure Therapeutics during the fourth quarter worth $2,118,000. 90.98% of the stock is owned by hedge funds and other institutional investors.

About OnKure Therapeutics

OnKure Therapeutics, Inc (NASDAQ: OKUR) is a clinical-stage biopharmaceutical company focused on the development of novel therapies for oncology and autoimmune diseases. Headquartered in Westlake Village, California, OnKure is advancing small molecule drug candidates designed to modulate key signaling pathways implicated in cancer cell growth and immune system function.

The company’s lead oncology asset, OKI-179, is an orally available histone deacetylase (HDAC) inhibitor being evaluated in Phase I and Phase II clinical studies for a range of solid tumors.